Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 32c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Castle Biosciences Announces Second Quarter 2020 Results
August 10, 2020 4:05 PM EDT
Q2 2020 revenues of $12.7 million, compared to $10.7 million in Q2 2019
DecisionDx-Melanoma test report volume decreased 19% compared to Q2 2019
Gross margin of 83%
Positive operating cash flow
FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced its financial results for the second quarter and six months ended June 30, 2020.
While our second quarter financial results reflect COVID-19 impacts, thanks to the strong execution by our employees, we continue to successfully... More
